Round Table Discussion: The Clinician's View on Outcome Methodologies for Pharmacologic Trials in Mild, Moderate, and Severe Alzheimer's Disease

Abstract

Barry Reisberg: Alistair Burns, a researcher and a clinician, is very active in the International Psychogeriatric Association (IPA). He comes to us from the U.K., and will add a unique perspective. Sture Eriksson is from Umea, Sweden, and he is a geriatrician. He sees patients and he also has a research perspective and, more particularly for this meeting, he is the chairman ofthe IPA's research committee. Sandy Finkel is the current president of IPA. He's aclinician, he sees patients, and he does research both in nursing home settings and in outpatient, settings. Serge Gauthier is a neurologist. He comes to us from Montreal, Canada, and he is indeed a clinician and also a researcher and he is the director of the Canadian clinical trials consortium. Raymond Levy is the president-elect of the IPA. He is a professor at the Maudsley in London; he remains a clinician and he also has a truly longitudinal view of the field. Laurie Mallery is from Halifax. Nova Scoria. She's a geriatrician. She's very rnuch involved with patients, and she also has become involved in research and is familiar with research issues, and obviously lends a unique perspective.